- Ye P, Rodriguez F, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung Cxc chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519–528. doi:10.1084/jem.194.4.519.
- McMahon D, Gern J. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Pediatrics. 2011;128(Suppl 3):S140.2–S141. doi:10.1542/peds.2011-2107CCCC.
- Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. doi:10.1056/NEJMoa1512711.
- Schmader K, Oxman M. Varicella and herpes zoster. In: Goldsmith L, Katz S, Gilchrest B (eds.). Fitzpatrick’s Dermatology in General Medicine. New York, NY: McGraw-Hill; 2012. Chap. 194.
- Harpaz R, Ortega-Sanchez I, Seward J, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.
- Egeberg A. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2101–2102. doi:10.1056/NEJMc1610828.
- A study of ixekizumab (LY2439821) in participants with moderare-to-severe plaque psoriasis (IXORA-S) [NCT02561806]. ClinicalTrials.gov; 2015. https://clinicaltrials.gov/ct2/show/study/NCT02561806.
- A study of ixekizumab (LY2439821) compared to guselkumab in participants with moderate-to-severe plaque psoriasis (IXORA-R) [NCT03573323]. ClinicalTrials.gov; 2018. https://clinicaltrials.gov/ct2/show/study/NCT03573323.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 33, 2020 - Issue 3
Case Studies
Ixekizumab and herpes zoster in an erythrodermic patient
, BS, 
, , MD, , MD & , MD
Brett A. AustinDepartment of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texashttp://orcid.org/0000-0002-2354-1681
, MDhttp://orcid.org/0000-0002-2354-1681, , MD, , MD & , MD